First Trust Nasdaq Pharmaceuticals ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
First Trust Nasdaq Pharmaceuticals ETF FTXH
Morningstar’s Analysis FTXH
Will FTXH outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 52.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 7.57 | 3M | Healthcare |
AbbVie Inc | 7.29 | 3M | Healthcare |
Johnson & Johnson | 7.06 | 3M | Healthcare |
Merck & Co Inc | 6.74 | 2M | Healthcare |
Bristol-Myers Squibb Co | 6.31 | 2M | Healthcare |
Viatris Inc | 3.77 | 1M | Healthcare |
Cardinal Health Inc | 3.47 | 1M | Healthcare |
Biogen Inc | 3.46 | 1M | Healthcare |
Vertex Pharmaceuticals Inc | 3.31 | 1M | Healthcare |
Amgen Inc | 3.16 | 1M | Healthcare |